The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database.

🎯 Background & Rationale

Pleural mesothelioma (PM) is a rare, highly aggressive malignancy where prognosis has traditionally relied heavily on anatomic TNM stage and histologic subtype. However, significant outcome variability exists among patients with identical stages, highlighting an unmet need for improved prognostic tools. While various genomic alterations (BAP1, CDKN2A, NF2, TP53) and biomarkers like PD-L1 have been investigated, their independent prognostic value and ability to enhance traditional clinicopathologic staging models in a large, multi-institutional setting remained unclear. This study served as a pilot analysis for the International Association for the Study of Lung Cancer (IASLC) Ninth Edition Staging Project to determine whether genomic data add clinically meaningful prognostic information beyond standard anatomic TNM classification.

👥 Study Design & Population

• Study Type: Multicenter Retrospective Cohort Study / Pilot Database Analysis.
• Population: 556 eligible patients diagnosed with pleural mesothelioma between 2013 and 2022 across three institutions (Memorial Sloan-Kettering Cancer Center, University of Chicago, and Mesobank in Lyon, France).
• Sub-cohorts: Biomarker analyses included up to 452 cases assessed by immunohistochemistry (IHC) for BAP1, 200 cases for PD-L1, and 260 cases with somatic next-generation sequencing (NGS) data for key genes of interest (BAP1, CDKN2A, NF2, TP53, SETD2).

📈 Methodology & Rigor

The study evaluated somatic genomic alterations via targeted NGS and protein expression via IHC (for BAP1 and PD-L1). Overall survival (OS) was calculated using the Kaplan-Meier method and compared via log-rank tests. Univariate and multivariable Cox proportional hazards regression models were constructed—adjusting for clinical confounders including age, sex, performance status, histologic subtype, curative-intent resection, and T/M staging groups. Models were rigorously evaluated and compared using Harrell’s C-statistic (for discrimination) and pseudo-$R^2$ (for explained randomness), with bootstrap correction applied to adjust for overfitting optimism.

🔬 Key Findings

• Genomic Landscape & Frequencies: Pathogenic BAP1 alterations were most common (55.0% by NGS; 57.5% loss by IHC), followed by CDKN2A (36.2%), NF2 (23.8%), and TP53 (18.1%). CDKN2A and NF2 alterations were significantly more frequent in nonepithelioid subtypes ($p < 0.001$). PD-L1 expression ($\ge 1%$) was positive in 44.5% of tested cases.
• Prognostic Impact (Univariate/Multivariable):
  • Pathogenic alterations in CDKN2A, NF2, and TP53 were significantly associated with worse OS ($p \le 0.001$). CDKN2A exhibited the highest hazard ratio for poor survival (multivariable HR = 2.12).
  • Conversely, BAP1 alterations (via NGS) and BAP1 loss (via IHC) were significantly associated with better OS (multivariable HR = 0.58 for both).
  • PD-L1 expression showed no statistically significant association with OS ($p = 0.645$).
• Model Performance: Traditional clinical covariates alone yielded a C-statistic of 0.67 ($R^2 = 25.3$). While genomic alterations alone performed less strongly (C-statistic = 0.65; $R^2 = 20.8$), a combined model incorporating BAP1 alterations, any pathogenic alteration in CDKN2A, NF2, or TP53, and standard clinical covariates achieved the highest predictive power (C-statistic = 0.70; $R^2 = 37.0$).

⚖️ Critical Appraisal

• Strengths: Utilizes a robust, real-world, multi-institutional international cohort with expert manual variant annotation and whole-tissue section IHC, aligning directly with the IASLC staging initiatives.
• Limitations: Lack of central pathology review across all participating sites, relatively small numbers for certain rare genomic alterations, and limited data availability for germline BAP1 testing. Additionally, retrospective designs carry inherent selection biases regarding which patients undergo extensive molecular profiling or surgical resection.

💡 The Clinical Bottom Line

Genomic profiling—specifically testing for BAP1, CDKN2A, NF2, and TP53—provides independent, clinically meaningful prognostic data that significantly enhances traditional clinicopathologic staging in pleural mesothelioma. For the clinician, integrating molecular markers (such as tissue-based CDKN2A deletion or BAP1 loss) into baseline pathology reports moves us closer to precision-guided risk stratification, better patient counseling, and more informed therapeutic trial design.